Compound reference
Epitalon
Epitalon (also spelled epithalon) is a tetrapeptide. FDA explicitly distinguishes it from epithalamin, a pineal-gland polypeptide extract; findings for the extract should not be attributed to the tetrapeptide.[1]
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
FDA’s 2026 review identified human biomarker research but no clinical insomnia outcome evidence sufficient to establish epitalon effectiveness. A change in melatonin or a laboratory aging marker is not evidence of longer human life.[1]
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
Editorial assessment
These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.
Corrected the molecular identity distinction using FDA’s explicit footnote and separated biomarkers from clinical outcomes.
This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.
Explore the interaction evidence for this compound →2026-07. Regulatory document.
Inspected location: Identity p. 8, footnote 6; clinical effectiveness pp. 25–28
Study context and inspection recordSource inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.